The US Food and Drug Administration (FDA) has approved Medtronic’s Percept RC deep brain stimulation (DBS) system to help improve treatment for movement disorders.
This rechargeable neurostimulator joins the Medtronic Percept family, said to be the first and only DBS system with sensing capabilities, directionality and advanced programming options.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Percept family includes the Percept PC neurostimulator, BrainSense technology and SenSight directional leads.
It allows physicians to provide personalised treatment for patients with movement disorders such as essential tremor, Parkinson’s disease, dystonia as well as epilepsy.
Medtronic Neuroscience Portfolio, Neuromodulation business brain modulation vice-president and general manager Amaza Reitmeier said: “Our DBS therapy with exclusive BrainSense technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted.
“We are transforming brain modulation through sensing-enabled DBS and will continue to drive therapy innovation with the goal of many more peoples’ lives improved with Medtronic DBS therapy.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSaid to be the smallest and thinnest dual-channel neurostimulator for DBS, the Percept RC features BrainSense technology that is designed to capture brain signals. This provides healthcare providers with valuable insights to tailor therapy to patient needs.
The Percept RC’s battery technology offers less battery fade compared with other rechargeable devices, ensuring a long-lasting life of at least 15 years.
In a separate announcement, Medtronic has announced CE Mark approval for its MiniMed 780G insulin delivery system with Simplera Sync sensor.
The system is planned for a limited release in Europe early this year, followed by a phased commercial launch later in 2024.
The MiniMed 780G system is designed to offer automatic glucose adjustments every five minutes. It is also the only system with a Meal Detection feature designed to mitigate post-meal hyperglycemia.
